Alcohol-associated liver disease (ALD) is a major cause of liver transplantation and death worldwide, and its impact is only growing. In 2022, the annual cost of ALD in the United States was $31 billion. By 2040, this number could be as high as $66 billion. ALD has limited therapeutic options, so scientists are looking for new ways to target the molecular biology of ALD to help prevent its occurrence or reduce its severity.
This article was originally published on MedicalXpress.com